R1 RCM (NASDAQ:RCM – Get Rating) issued its earnings results on Monday. The healthcare provider reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.04), Briefing.com reports. R1 RCM had a return on equity of 30.22% and a net margin of 6.59%. The firm had revenue of $385.70 million for the quarter, compared to analysts’ expectations of $384.18 million. During the same period last year, the firm earned ($2.37) earnings per share. R1 RCM’s revenue for the quarter was up 12.6% on a year-over-year basis. R1 RCM updated its FY 2022 guidance to EPS.
Shares of R1 RCM stock traded up $0.75 during trading hours on Tuesday, hitting $19.86. The company had a trading volume of 10,003 shares, compared to its average volume of 1,276,233. The company’s 50-day moving average is $25.25 and its two-hundred day moving average is $24.55. R1 RCM has a twelve month low of $18.71 and a twelve month high of $27.86. The company has a debt-to-equity ratio of 2.19, a current ratio of 1.43 and a quick ratio of 1.43. The company has a market cap of $5.53 billion, a P/E ratio of -8.89, a price-to-earnings-growth ratio of 2.46 and a beta of 0.86.
A number of equities research analysts have recently issued reports on RCM shares. Robert W. Baird boosted their price target on shares of R1 RCM from $29.00 to $32.00 in a research note on Thursday, March 3rd. Deutsche Bank Aktiengesellschaft reduced their price target on shares of R1 RCM from $30.00 to $28.00 in a research note on Tuesday. Zacks Investment Research raised shares of R1 RCM from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research note on Thursday, April 21st. Finally, Guggenheim began coverage on shares of R1 RCM in a research note on Wednesday, April 13th. They set a “neutral” rating on the stock. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, R1 RCM currently has an average rating of “Buy” and an average target price of $29.25.
R1 RCM Company Profile (Get Rating)
R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers.
- Get a free copy of the StockNews.com research report on R1 RCM (RCM)
- High-Yield Deep-Value LCI Industries Exceeds All Expectations
- Shopify (NYSE: SHOP) Approaches Key Support Level
- The Low In Lordstown Motors May Not Be The Last
- Intuitive Surgical is an Intuitive Buy
- Follow The Money To Cigna
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.